


0 9/029,479
PCT/IB 96 / 01021
24. 10. 96



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:




UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 9, 1996

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/003,114

FILING DATE: September 1, 1995



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

T. Lawrence
T. LAWRENCE
Certifying Officer

PATENT APPLICATION SERIAL NO. 60/003114

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

290 SB 10/12/95 60003114
1 214 75.00 CK PR-314 (TAU)

PTO-1556
(5/87)

Case Docket No. PR-314 (TAU)

Date: September 1, 1995

PROVISIONAL APPLICATION

ASSISTANT COMMISSIONER FOR PATENTS
Box: Provisional Patent Applications
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is a PROVISIONAL APPLICATION of:

Inventor(s): 1-00 Sara Lavi, an Israeli citizen
6 Thuaat Hameri Street, Kyriat Ono 55060, Israel ILX

For: MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE
2C - PP2C - EXPRESSION IN TUMOR CELLS FOR CANCER
THERAPY, PREVENTION AND DETECTION

Enclosed are:

- ☒ 47 sheets of specification
- ☒ 15 sheets of drawings (INFORMAL)
- ☒ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27
- ☒ Small Entity - Basic Fee \$ 75.00
- ☐ Large Entity - Basic Fee \$150.00
- ☐ Please charge my Deposit Account No. 11-1449 in the amount of \$ _____
A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of \$75.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 11-1449. A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 CFR 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.

The following attorneys are acting on behalf of the inventor(s):

K.I. Kohn 30,955 I.N. Montgomery 38,972

Respectfully submitted,

KOHN & ASSOCIATES


30500 Northwestern Hwy.
Suite 410
Farmington Hills, MI 48334
(810) 539-8472

Ilene N Montgomery
Reg. No. 38,972

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" Label No. EG101942414US Date of Deposit: 9-1-95
I hereby certify that this paper and fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Ilene N. Montgomery



PR-314 (TAU)

-1-

60/003114

MANIPULATION AND DETECTION OF PROTEIN
PHOSPHATASE 2C - PP2C - EXPRESSION IN TUMOR
CELLS FOR CANCER THERAPY, PREVENTION AND
DETECTION

5

BACKGROUND OF THE INVENTION

TECHNICAL FIELD

10 The present invention relates to detection and
methods of treating cancer by utilizing the gene human
type protein phosphatase 2C (PP2C) and gene products
thereof, and preparing native and transgenic organisms
15 in which the gene products encoded by the PP2C gene or
its homolog in other species are artificially produced,
or the expression of the native PP2C gene is modified
and kits for the practice of the invention.

BACKGROUND ART

20 Gene amplification is one of the distinct
abnormalities associated with malignant cells and
transformed cell lines. This phenomenon is part of the
genetic instability characterizing neoplastic cells and
occurs rarely in normal cells. If the transformed
25 phenotype can be reversed, i.e. the cells loose their
neoplastic phenotype, thereby reinstating normal
cellular growth the cancerous cells can be controlled
providing a treatment.

 Adeno associated viruses are members of the family
30 of parvoviruses for which tumor suppressive properties
have already been described in 1960 (for review see
Rommelaere and Tattersal, 1990). They are a group of
small viruses, with a ssDNA genome of approximately
5000 nucleotides, characterized by identical
35 palindromic termini of 154 bases. The left part of the
AAV genome encodes four multifunctional, overlapping,

non-structural proteins (Rep78, Rep68, Rep52 and Rep40) which are translated from differentially spliced mRNA driven by the P5 and P19 promoters. In the right part of the genome three overlapping capsid polypeptides (VP1 -VP3) are encoded from the P40 promoter (Berns, 1990; Leonard and Berns, 1994). These extremely small DNA viruses are represented in vertebrates by two genera, the autonomously replicating and the helper dependent parvovirus (Siegl et al., 1985).

The helper-dependent adeno-associated viruses (AAV) depend for their replication on coinfecting helper virus (Young and Mayor, 1979ab), or on conditions of genotoxic stress (Yakobson et al., 1987) and comprise agents infecting humans without apparent disease (Cukor et al., 1984). Helper viruses are adenoviruses (Atchison et al., 1965), herpes group viruses (Salo and Mayor, 1979) and vaccinia virus (Schlehofer et al., 1986). The helper viruses share the ability to induce chromosomal damage early in their infection cycle (Schlehofer and zur Hausen, 1982).

Anti tumor activity of adeno associated virus:

Tumor suppressive properties have been found for AAV (for review see Schlehofer, 1994). It has been shown that the development of tumors induced in rodents by adenoviruses, herpes viruses or by transplantation of cells transformed by these viruses could be inhibited by infecting the animal cells with AAV (Kirschstein et al. 1968; Mayor et al., 1973; de la Maza and Carter, 1981; Ostrove et al., 1981). The in-vivo findings of tumor suppression are paralleled by results showing inhibition of cellular transformation in-vitro. This could be shown for cells of different origin (hamster and mouse) transformed by viruses or by activated oncogenes. Compared with controls, cells infected with AAV or transfected with specific AAV DNA

sequences displayed decreased focus formation and saturation density indicating inhibition of transformation-associated traits (Casto and Goodheart, 1972; Katz and Carter, 1986; Hermonat, 1989; Hermonat, 1994).

In addition, there are seroepidemiologic findings in the human population, showing that cancer patients exhibit antibodies to AAV less frequently than matched control individuals. Three independent studies carried out in the USA (Mayor et al., 1976), Belgium (Sprecher-Goldberger et al., 1971) and Germany (Georg-Fries et al., 1984) using different serologic techniques, have found a high prevalence of antibodies to AAV (types 2, 3, and 5) in the normal population contrasting with a relatively low frequency of seropositivity in patients with cancer.

It would be useful to develop therapeutic methods for controlling cell transformation. As the above information indicates it is possible to reverse cell transformation or to specifically kill the transformed cell. It would be useful to find human cellular mechanisms that can be controlled to reverse cell transformation.

SUMMARY OF THE INVENTION AND ADVANTAGES

According to the present invention, a method and kit of detecting cancer in a patient by detecting activity of the gene coding for human type protein phosphatase 2C (PP2C) and genetic polymorphisms thereof in a specimen containing cells isolated from the patient is disclosed. The invention further provides a method of treating cancer including the steps of first determining the type of cancer and cells expressing the cancer and then preparing a vector which will specifically target the cancer cells and can include

regulatory elements to control the expressibility of PP2C. The vector is then administered to the patient. Alternatively an antisense vector can be prepared.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

FIGURE 1A-E are photomicrographs of Control (C) and MNNG (10 $\mu\text{g/ml}$) treated (T) CO60 and 9-3 cells which were trypsinized 72 hours after treatment and immobilized onto a glass-microscopic slide followed by the in-situ hybridization procedure. SV40 biotinylated probe was conjugated with fluorescein labeled Avidin (yellow). The chromosomes were stained with Propidium Iodide (red). The fluorescent signal was detected under a fluorescent microscope at 495nm.

FIGURE 2A-B are graphs of a FACS analysis of CO60 and two AAV/neo cell lines 913 and 916 as prepared for cell cycle analysis. 24 hours after seeding the cell were trypsinized and washed with PBS. The cells were resuspended in 1ml buffer containing 0.1% sodium citrate, 0.1% triton X-100 and 50 μg propidium iodide, and then processed in the FACS.

FIGURE 3A-D are photomicrographs showing in-vivo detection of programmed cell death. Treated cells or control cells were grown on pretreated coverslips in Petri dishes. 48 hours after seeding the coverslips were washed with PBS, pH 7.5 at 37°C for 5 minutes and covered with dye mix (100 $\mu\text{g/ml}$ acridine orange and 100 $\mu\text{g/ml}$ ethidium bromide in PBS pH 7.5), then placed upside down on a glass slide and immediately examined

by fluorescence microscopy. Note the shrinkage of the cytoplasm in treated 9-3.

FIGURE 4A-D are photomicrographs showing In-situ detection of programmed cell death in cells grown on pretreated coverslips in 60mm Petri dishes. 48 hours after MNNG treatment (2.0 μ g/ml or 10 μ g/ml MNNG for 9-3 and CO60 respectively) the cells were processed as described by Gavrieli et al. (1992) and Wijsman et al. (1993).

FIGURE 5 is a photograph of a Southern Blot analysis showing CHINT is associated with AAV integration in different AAV/neo cell lines. Southern blot analysis of different AAV/neo clones, CO60 DNA, digested with BglII, and hybridized with "CHINT" probe. 9-1, 2, 3, 4 and 5 on AAV/neo cell lines. 93R is a revertant that lost the whole chromosome containing the AAV. A6 is a mouse cell line.

FIGURE 6 is a photomicrograph showing AAV integration in 9-3 cells. 9-3 metaphase cells were immobilized onto glass microscope slides, followed by in-situ hybridization procedure. pJDT277 biotinylated probe was conjugated with Fluorescein labeled avidin (yellow). The chromosomes were prestained with Propidium Iodide. Arrows point to the AAV integration sites.

FIGURE 7 is a schematic representation of the organization of the integrated AAV and the flanking cellular sequences in 9-3 cells. A genomic library was prepared from C9-3 cells using the EMBL-4 lambda phage and scored for AAV positive clones. A clone of 13Kb- λ SL9-1 was isolated and later subcloned to a blue-script vector. Plasmids pSL9-11 (13Kb), pSL9-8 (10Kb) and pSL9-6 (3Kb) were obtained as indicated in the figure.

FIGURE 8A-B shows (A) the homology between CHINT and a sequence from human DNA from cosmid DNA MMDB

containing the 5' end of the PP2C RNA and (B) the homology between MMDB and the human PP2C cDNA.

FIGURE 9A-B wherein (A) is a photograph of a Southern Blot Analysis showing AAV is adjacent to the gene coding to PP2C in 9-3 cells. The Southern blot analysis of genomic DNA, from CO60 and 9-3 cells digested by EcoRI, or XbaI was hybridized sequentially with the following probes: 1) AAV; 2) CHINT; and 3) Rat PP2C probes. The CHINT and the PP2C sequences are adjacent (4Kb EcoRI fragment). The AAV CHINT and PP2C are in a close proximity in 9-3 cells (the 5.6Kb XbaI fragment). (B) pSL9-6 is adjacent to PP2C in the wild type Chinese hamster cells. BamHI digested RNA from the Chinese hamster neo cells was hybridized to pSL9-6 and PP2C probes. A common fragment of ~8.5Kb appeared in all cell lines including CO60. The same fragment hybridized also to CHINT probe (data not shown).

FIGURE 10A-C are photographs of a Southern blot analysis of DA3 (lane 8) and DA3J1-DA3J1 cells lines (lanes 1-7). Genomic DNA was digested with BglII. The plots were hybridized sequentially with an AAV/neo JDT277, pSL9-6 and PP2C PCR probes. A 4Kb fragment hybridized to the AAV probe and pSL9-6 probe in J3 (lane 3), J4 (lane 4) and J6 (lane 6). A fragment smaller than 4Kb hybridized to both AAV and PP2C probe in J1 (lane 1), J2 (lane 2), J5 (lane 5) and J6 (lane 6).

FIGURE 11 is a photograph which shows the alteration in PP2C mRNA in response to carcinogen treatment. Forty μ g of total RNA were isolated from CO60 and C9-3 cells 10 hours after treatment with MNNG (7.5 μ g/ml and 2.5 μ g/ml respectively), and from untreated cells and fractionated on a denaturing gel (1.2% agarose/6.6% formaldehyde gel). The gel was blotted and hybridized consecutively with 32P-labeled rat PP2C cDNA (A) pSL9-1^{DNA} (B) and rRNA cDNA (C).

FIGURE 12A-D are photographs which show rescue of the transformed phenotype by transfection with PP2C cDNA. A full length cDNA encoding rat type 2C protein phosphatase (~2.4Kb) was isolated from rat embryo cDNA library in lambda Zap (kindly provided by M. Oren from the Weizmann Institute of Science). The cDNA is expressed from a CMV promoter. PP2C clone (5 µg) was stably transfected into AAV/neo cells (C9-3) (C9-3 passage 17) together with a gpt plasmid (5 µg) conferring resistance to mycophenolic acid (MPA). The plasmids were introduced using the calcium phosphate co-precipitation method. Following a three day expression period, 2×10^5 cells were plated on soft agar with the selective agent MPA. A control plasmid containing the 3'UTR of non relevant gene (cyclin G) was cotransfected with the gpt plasmid. One month later the colonies were counted. In the figure A and B, control plasmid; C and D, PP2C DNA. PP2C transfected cells regained their capability to grow in soft agar.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention discloses a method of detecting cancer in a patient by detecting activity of the gene coding for human type protein phosphatase 2C (PP2C) and genetic polymorphisms thereof in a specimen containing cells isolated from the patient.

Polymorphisms are variants in the gene sequence. They can be sequence shifts found between different ethnic and geographic locations which, while having a different sequence, produce functionally equivalent gene products, isoforms. Polymorphisms also encompass variations which can be classified as alleles and/or mutations which can produce gene products which may have an altered function. Polymorphisms also encompass

variations which can be classified as alleles and/or mutations which either produce no gene product or an inactive gene product.

5 Samples can be biopsied material from suspected precancerous lesions or any tissue or bodily fluid which can be assayed for PP2C activity.

In an embodiment the detection of PP2C activity is by assaying the specimen for mRNA complementary to PP2C DNA including polymorphisms thereof with an assay
10 selected from the group consisting of in situ hybridization, Northern blotting and reverse transcriptase - polymerase chain reaction.

The present invention also provides for a kit for detecting PP2C activity. The kit includes molecular
15 probes for mRNA for PP2C polymorphisms thereof and detection means for detecting the molecular probe and thereby the mRNA.

In an alternative method, the detecting of PP2C activity is by assaying the specimen for a PP2C gene
20 product including polymorphisms thereof with an assay selected from the group consisting immunohistochemical and immunocytochemical staining, ELISA, RIA, immunoblots, immunoprecipitation, Western blotting, functional assays for phosphatase activity and protein
25 truncation test.

The present invention also provides for a kit for detecting a gene product interacting with PP2C gene products. The kit can include an antibody which
30 recognizes the gene products including polymorphisms thereof, and detection means for detecting the binding of the antibody thereby indicating the presence of the gene product.

The invention further provides a method of treating cancer including the steps of first
35 determining the type of cancer and cells expressing the cancer and then preparing a vector which will

specifically target the cancer cells and can include regulatory elements to control the expressibility of PP2C. The vector is then administered to the patient. Alternatively an antisense vector can be prepared. In
5 a preferred embodiment the AAV virus and/or CHINT sequences are used in the vector. CHINT is a cellular sequence which was recombined into the AAV in 9-3 cells; the sequence is set forth in Figure 8A. The vector can either reestablish regulatory control of
10 PP2C expression thereby leading to differentiation or alternatively, differentiation and cell death.

There are several elements in AAV and CHINT that might be used to control PP2C expression:

1. PP2C has a very long 5' and 3' UTR (they are larger
15 than the coding capacity). Specific folding of the RNA and interaction with specific sets of proteins might effect its expression dramatically. At certain stages there might different modes of folding and different proteins may interact with the RNA and thus regulate
20 its expression.
2. The CHINT sequences involved in the integration have very interesting motifs which might be used for the site specific integration. Moreover, applicant has preliminary data suggesting that the CHINT fragment,
25 possibly together with the AAV sequences adjacent to it, are responsible for the suppression of DNA amplification.

The invention further provides a method of preventing cancer by using an AAV vector for cancer
30 prevention that only functions specifically in cells in which PP2C is improperly activated. The modified AAV will be used at high dose to infect healthy populations. The dormant integrated virus will interrupt PP2C expression and will either prevent the
35 appearance or the initiation of tumor cells.

The present invention provides an antibody, either polyclonal or monoclonal, which specifically binds to a polypeptide/protein encoded by the PP2C gene. In preparing the antibody, either the entire protein or peptide sequences can be used as an immunogen as well as polymorphisms thereof. The invention further provides antibodies that will recognize the special structures at the 5'UTR or the RNA-proteins complexes responsible for the controlled expression of PP2C. Antibody which recognizes specifically the special RNA structures is also provided.

The antibodies may be either monoclonal or polyclonal. Conveniently, the antibodies may be prepared against a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof may be isolated and used as the immunogen. Such proteins or peptides can be used to produce antibodies by standard antibody production technology well known to those skilled in the art as described generally in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988.

For producing polyclonal antibodies a host, such as a rabbit or goat, is immunized with the protein or peptide, generally with an adjuvant and, if necessary, coupled to a carrier; antibodies to the protein are collected from the sera.

For producing monoclonal antibodies, the technique involves hyperimmunization of an appropriate donor, generally a mouse, with the protein or peptide fragment and isolation of splenic antibody producing cells. These cells are fused to a cell having immortality, such as a myeloma cell, to provide a fused cell hybrid which has immortality and secretes the required antibody. The cells are then cultured, in bulk, and

the monoclonal antibodies harvested from the culture media for use.

The antibody can be bound to a solid support substrate or conjugated with a detectable moiety or be both bound and conjugated as is well known in the art. (For a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone and Thorpe, *Immunochemistry in Practice*, Blackwell Scientific Publications, Oxford, 1982.) The binding of antibodies to a solid support substrate is also well known in the art. (see for a general discussion Harlow and Lane *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Publications, New York, 1988) The detectable moieties contemplated with the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, β -galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, ^{14}C and iodination.

The present invention provides vectors comprising an expression control sequence operatively linked to the nucleic acid sequence of the PP2C gene and portions thereof as well as polymorphic sequences thereof. The present invention further provides host cells, selected from suitable eucaryotic and procaryotic cells, which are transformed with these vectors.

The vectors can be introduced into cells or tissues by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1992), in Ausubel et al., *Current Protocols in*

Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989), Chang et al., *Somatic Gene Therapy*, CRC Press, Ann Arbor, MI (1995), Vega et al., *Gene Targeting*, CRC Press, Ann Arbor, MI (1995) and Gilboa, et al (1986) and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. Introduction of nucleic acids by infection offers several advantages over the other listed methods. Higher efficiency can be obtained due to their infectious nature. Moreover, viruses are very specialized and typically infect and propagate in specific cell types. Thus, their natural specificity can be used to target the vectors to specific cell types *in vivo* or within a tissue or mixed culture of cells. Viral vectors can also be modified with specific receptors or ligands to alter target specificity through receptor mediated events.

More specifically, such vectors are known or can be constructed by those skilled in the art and should contain all expression elements necessary to achieve the desired transcription of the sequences. Other beneficial characteristics can also be contained within the vectors such as mechanisms for recovery of the nucleic acids in a different form. Phagemids are a specific example of such beneficial vectors because they can be used either as plasmids or as bacteriophage

vectors. Examples of other vectors include viruses such as bacteriophages, baculoviruses and retroviruses, DNA viruses, cosmids, plasmids, liposomes and other recombination vectors. The vectors can also contain
5 elements for use in either procaryotic or eucaryotic host systems. One of ordinary skill in the art will know which host systems are compatible with a particular vector.

Recombinant methods known in the art can also be
10 used to achieve the sense, antisense or triplex inhibition of a target nucleic acid. For example, vectors containing antisense nucleic acids can be employed to express protein or antisense message to reduce the expression of the target nucleic acid and
15 therefore its activity.

A specific example of DNA viral vector for introducing and expressing recombinant sequences is the adenovirus derived vector Adenop53TK. This vector expresses a herpes virus thymidine kinase (TK) gene for
20 either positive or negative selection and an expression cassette for desired recombinant sequences. This vector can be used to infect cells that have an adenovirus receptor which includes most cancers of epithelial origin as well as others. This vector as
25 well as others that exhibit similar desired functions can be used to treat a mixed population of cells and

can include, for example, an *in vitro* or *ex vivo* culture of cells, a tissue or a human subject.

Additional features can be added to the vector to ensure its safety and/or enhance its therapeutic
5 efficacy. Such features include, for example, markers that can be used to negatively select against cells infected with the recombinant virus. An example of such a negative selection marker is the TK gene described above that confers sensitivity to the
10 antibiotic gancyclovir. Negative selection is therefore a means by which infection can be controlled because it provides inducible suicide through the addition of antibiotic. Such protection ensures that if, for example, mutations arise that produce altered
15 forms of the viral vector or recombinant sequence, cellular transformation will not occur. Features that limit expression to particular cell types can also be included. Such features include, for example, promoter and regulatory elements that are specific for the
20 desired cell type.

In addition, recombinant viral vectors are useful for *in vivo* expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity. Lateral infection is
25 inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect

neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.

As described above, viruses are very specialized infectious agents that have evolved, in many cases, to elude host defense mechanisms. Typically, viruses infect and propagate in specific cell types. The targeting specificity of viral vectors utilizes its natural specificity to specifically target predetermined cell types and thereby introduce a recombinant gene into the infected cell. The vector to be used in the methods of the invention will depend on desired cell type to be targeted and will be known to those skilled in the art. For example, if breast cancer is to be treated then a vector specific for such epithelial cells would be used. Likewise, if diseases or pathological conditions of the hematopoietic system are to be treated, then a viral vector that is specific for blood cells and their precursors, preferably for the specific type of hematopoietic cell, would be used.

Retroviral vectors can be constructed to function either as infectious particles or to undergo only a single initial round of infection. In the former case, the genome of the virus is modified so
5 that it maintains all the necessary genes, regulatory sequences and packaging signals to synthesize new viral proteins and RNA. Once these molecules are synthesized, the host cell packages the RNA into new viral particles which are capable of undergoing further
10 rounds of infection. The vector's genome is also engineered to encode and express the desired recombinant gene. In the case of non-infectious viral vectors, the vector genome is usually mutated to destroy the viral packaging signal that is required to
15 encapsulate the RNA into viral particles. Without such a signal, any particles that are formed will not contain a genome and therefore cannot proceed through subsequent rounds of infection. The specific type of vector will depend upon the intended application. The
20 actual vectors are also known and readily available within the art or can be constructed by one skilled in the art using well-known methodology.

The recombinant vector can be administered in several ways. If viral vectors are used, for example,
25 the procedure can take advantage of their target specificity and consequently, do not have to be administered locally at the diseased site. However,

local administration can provide a quicker and more effective treatment, administration can also be performed by, for example, intravenous or subcutaneous injection into the subject. Injection of the viral
5 vectors into a spinal fluid can also be used as a mode of administration, especially in the case of neurodegenerative diseases. Following injection, the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection.

10 An alternate mode of administration of of a PP2C vector can be by direct inoculation locally at the site of the disease or pathological condition or by inoculation into the vascular system supplying the tumor with nutrients. Local administration is
15 advantageous because there is no dilution effect and, therefore, a smaller dose is required to achieve expression in a majority of the targeted cells. Additionally, local inoculation can alleviate the targeting requirement required with other forms of
20 administration since a vector can be used that infects all cells in the inoculated area. If expression is desired in only a specific subset of cells within the inoculated area, then promoter and regulatory elements that are specific for the desired subset can be used to
25 accomplish this goal. Such non-targeting vectors can be, for example, viral vectors, viral genome, plasmids, phagemids and the like. Transfection vehicles such as

liposomes can also be used to introduce the non-viral vectors described above into recipient cells within the inoculated area. Such transfection vehicles are known by one skilled within the art.

- 5 In a preferred embodiment, a virus vector based on modified AAV is used. AAV virus has been shown to integrate into the human genome in chromosome 19q13.3 but not into the PP2C gene. The human PP2C regulatory region has some of the motifs required for AAV
- 10 integration, a slight manipulation of the viral AAV sequences will facilitate its integration to the PP2C in human.

 The present invention provides for transgenic PP2C gene and polymorphic PP2C gene animal and cellular

15 (cell lines) models as well as for knockout PP2C models. These models are constructed using standard methods known in the art and as set forth in United States Patents 5,387,742, 5,360,735, 5,347,075, 5,298,422, 5,288,846, 5,221,778, 5,175,385,

20 5,175,384, 5,175,383, 4,736,866 as well as Burke and Olson, (1991), Capecchi, (1989), Davies et al., (1992), Dickinson et al., (1993), Huxley et al., (1991), Jakobovits et al., (1993), Lamb et al., (1993), Rothstein, (1991), Schedl et al., (1993), Strauss et

25 al., (1993). Further, patent applications WO 94/23049, WO 93/14200, WO 94/06908, WO 94/28123 also provide information.

To investigate the role of AAV in tumor suppression an AAV/neo virus JDT277 was introduced into SV40 transformed Chinese hamster (C060 and OD4 cells) and mouse mammary tumor cells (DA3). C060 is a cell
5 line of SV40 transformed Chinese hamster embryo cell lines (Lavi, 1981). The OD cell line was established by transfection of Chinese hamster embryonic cells with origin deleted SV40 DNA (Lavi, 1985). The mouse DA3
10 cell line was derived from mammary tumors syngeneic to BALB/c mice (Sotomayor et al, 1991). JDT277 virus contains the portion of the AAV2 genome, which encodes the viral Rep proteins, the AAV terminal inverted repeats (TIRs) and the prokaryotic neomycin
phosphotransferase gene (neo), conferring resistance to
15 G418. The neo gene was inserted at nucleotide 1882, resulting in carboxy terminus truncated Rep proteins. The truncation of the rep proteins does not affect the ability of the AAV/neo virus to replicate in Adenovirus coinfecting human cells.

20 Single colonies were isolated and amplified by serial passages in the presence of G418. The resistant cells were designated 9-1 to 9-5 for cells derived from C060 cells and A20-A29 for cells derived from OD4 cells. The cell lines derived from the mouse cells DA3
25 were designated J1-J15.

Alterations of the transformed phenotype:

Following AAV integration the cells lost several of their transformed characteristics.

5 1. Suppression of SV40 DNA amplification.

A characteristic trait of tumor cells is their capability to amplify DNA. CO60 cells are used as a model system to study gene amplification and SV40 amplification can be induced in the cells as a results
10 of treatment with carcinogens (Lavi, 1981; Aladjem and Lavi, 1992). Following AAV/neo virus integration, the cells were incapable to amplify SV40. Most AAV/neo cell lines derived from CO60 cells lost their capability to amplify SV40 upon treatment with
15 carcinogen in contrast to the parental CO60 cells (Tal Burstyn, 1993). An example for this suppression is presented in Figure 1. Extracts from AAV/neo cells derived from both OD4 and CO60 cells lost their capability to amplify SV40 in-vitro (Winocour et al.,
20 1992; Tal Burstyn, 1993).

2. The cells harboring the integrated SV40 became highly sensitive to treatment with UV or MNNG. (Winocour et al., 1992).

3. The transformed cells lost their capability to grow in soft agar, a characteristic typical to transformed cells.

5 4. The cells displayed apoptotic phenotype as measured by

- a) the cell cycle pattern (Figure 2),
- b) the condensation and fragmentation of the chromatin (Figure 3) and cytoplasm condensation and
- 10 fragmentation of chromatin,
- c) by the breaks in the chromosomal DNA (Figure
- 4).

The integrated AAV in the AAV/neo cells

15 Analysis of cell extract derived from the Chinese hamster A20-A29, 9-1 to 9-5 and the mouse DA3 derivatives for the expression of rep proteins by immunoblotting with anti-Rep antibodies demonstrated that in all cell lines the authentic Rep products were

20 not present. In some cell lines a short protein, probably a truncated protein, reacted with the anti-Rep antibodies (Winocour et. al., 1992).

PCR analysis of most cell lines for the presence of the intact promoter region demonstrated that in most

25 cell lines the promoter region of the Rep protein was reorganized as a result of deletions, insertions and

rearrangements of the AAV sequences thus eliminating the expression of the authentic Rep proteins.

Applicant focused on the analysis of one of the cell lines, 9-3, derived from CO60 cells. As shown in Figure 6 the integrated AAV undergoes duplication in this cell line and the chromosome harboring the AAV contains two regions containing the integrated AAV genomes. Note that this duplication of AAV probably resulted from the massive rearrangement which occurred in the Chinese hamster genome following AAV integration. In all cell lines studied so far by in-situ hybridization (6 independent cell lines) the chromosome harboring the integrated AAV was altered and was different in many respects from all the typical Chinese hamster chromosomes, thus the identity of the chromosome could not be established.

The integrated AAV and flanking cellular sequences were cloned into a phage (Figure 7). As shown in Figure 7 the viral genome underwent several changes. Sequences downstream to the AAV p5 promoter were deleted and replaced by a cellular fragment "CHINT". In addition, deletions and rearrangements in the 5' portion of the AAV/neo genome were observed. In contrast, the region coding for the Neo gene and the 3' end of the viral genome remained intact. (Similar alterations were observed in all AAV/neo Chinese hamster and mouse cell lines tested).

The "CHINT" sequences were used as a probe to analyze AAV integration site in different AAV/neo Chinese hamster clones (Figure 5). In several AAV/neo clones there was a shift in this fragment suggesting
5 that the size of this fragment was altered upon AAV integration. Some of the shifted bands also hybridized to AAV probe demonstrating that AAV indeed integrated into this region. A probe from the subcloned plasmid pSL9-6 derived from the flanking cellular sequences
10 (Figure 7) was hybridized to the mouse DA3 AAV/neo cells and in most cases it was associated with AAV integration. These results suggest that the AAV integration site in Chinese hamster might be similar to the one in mouse cells (data not shown).

15 Sequence comparison using Genetic Computer Group Inc. software demonstrated that the CHINT sequences are 58.3% homologous to a sequence in the human chromosome 19q13.3. This human sequence is a part of a 106Kb fragment which was automatically sequenced and analyzed
20 (Martin-Gallardo et al., 1992) (GENBANK accession number: M89651). The region which showed homology to the CHINT sequences was a part of the gene coding for human type protein phosphatase 2C (PP2C). According to the cDNA sequence of this gene the exact region
25 homologous to CHINT is located upstream to the 5'UTR of PP2C (Figure 8) (GENBANK accession numbers: human PP2C S87759, rabbit PP2C S87757).

Using a PCR fragment derived by using two primers for PP2C, cDNA DNA from 9-3 was probed and a XbaI fragment was found which hybridized to AAV, CHINT and PP2C, and an EcoRI fragment was found which hybridized to PP2C and CHINT in CO60 DNA. Thus, PP2C is indeed localized in very close proximity to CHINT in CO60 cells and is at the integration site in 9-3 cells. In-situ hybridization confirmed this conclusion (Figure 9A).

10 In both Chinese hamster (CO60 and OD4) and mouse cells (DA3) a portion of the PP2C sequences was adjacent to the CHINT hamster sequence present in pSL9-6 (Figure 7) which was derived from the lambda clone of the AAV integration site. Thus in both the
15 normal Chinese hamster and mouse chromosome PP2C is indeed localized at very close proximity, less than 4Kb from the sequences surrounding the integrated AAV (Figure 9B).

PP2C is a protein serine/threonine phosphatase
20 (Cohen 1989). It is unique amongst phosphatases since it requires magnesium and is sensitive to certain phosphatase inhibitors such as okadaic acid (Cohen 1991). The PP2C family consists of two cytoplasmic isoenzymes in mammalian tissues (McGowan and Cohen,
25 1987) and at least three PP2C-like enzymes in yeast show the same enzymatic and biochemical properties.

The two mammalian isoenzymes are monomers but differ slightly in molecular mass (44KDa and 42KDa).

Little is known about the role of PP2C in the cell or about its native substrates mainly because of the
5 lack of specific inhibitors for PP2C. In *Schizosaccharomyces pombe* it has been shown that PP2C-like enzymes are important for heat shock response and in osmoregulation (Shiozaki, 1995; Shiozaki, 1994). In *Saccharomyces cerevisiae* PP2C-like activity has been
10 implicated in the regulation of tRNA splicing and cell separation (Robinson et al., 1994). In neural cells PP2C might have a role in the regulation of the Ca⁺⁺-independent activity of Ca⁺⁺/calmodulin dependent protein kinase II (Fukugana, 1993). Otherwise,
15 information about PP2C is scarce.

PP2C might be a cell marker itself. We do not know anything yet about its expression in tumor cells. There is a manuscript suggesting that PP2C might have a role during myogenic differentiation. (Ohishi, 1992).

20 Furthermore, in mouse DA3 cells harboring the integrated AAV genome the AAV sequences were associated with PP2C or with fragment 6 or with both (Figure 10).

Unexpectedly, analysis of the PP2C mRNA in the AAV/neo cells demonstrated that the transcription of
25 the gene was reduced upon treatment with DNA damaging agents in contrast to the parental SV40 transformed

cells in which PP2C was induced following the treatment (Figure 11).

The following is the densitometry analysis of the hybridization signals

	CO60 C	CO60 T	CO60 T CO60 C	C9-3C	C9-3T	C9-3T C9-3C
PP2C rRNA	0.15	0.31	2.06	0.26	0.15	0.57

The transcription of PP2C in C9-3 was reduced upon treatment with MNNG in contrast to the parental SV40 transformed cells in which PP2C was induced following treatment.

The intact cDNA coding for PP2C was cloned from a cDNA library (provided by M. Oren, the Weizmann Institute of Science, Rehovot) and PP2C clone was stably introduced into the AAV/neo cells which lost the transformed phenotype following AAV-integration. The transformed features were rescued following the expression of the PP2C clone in the PP2C neo cells, the cells regained the properties of transformed cells, grew in soft agar and lost their apoptotic phenotype (Figure 12). Similar cells which were transfected in the same efficiency with a control plasmid containing a truncated cDNA of non relevant gene did not regain the capability to grow in soft agar.

From these studies it is apparent that PP2C has a key role in the initiation and/or maintenance of transformed cells.

PP2C might be a marker by itself. We do not know anything yet about its expression in tumor cells. There is a manuscript suggesting that PP2C might have a role during myogenic differentiation. (Ohishi, 1992).

PP2C appears to be important in development. The high conservation of the gene and protein throughout

evolution, the specific control signals including IRES (internal ribosome entry site) at the 5'UTR support this. The findings by other laboratories that AAV infection effects specifically tumor cells might have two explanations: 1) the virus does not infect normal cells or cannot integrate into their genome in a specific manner. 2) alternatively, if AAV integrates into PP2C in normal cells the disruption of this gene might not effect them. The fact that the inactivation of only one allele of PP2C is responsible for the changes in the transformed phenotype and that the introduction of a functional PP2C cDNA clone rescues the transformed phenotype suggest that PP2C is important indeed. Applicant also noticed that in highly tumorigenic Chinese hamster cells the whole chromosome carrying PP2C is duplicated 3,4, and even 5 times.

In human, on the same chromosome, in a close vicinity to PP2C there is an important tumor specific marker called cancer embryonic antigen (CEA), which appears in most tumor cells. Both genes are mapped to chromosome 19q13.3. Targeting the treatment to cells carrying a marker like CEA might help. (It might be possible that CEA by itself is not relevant to cancer but it is associated with the enhanced expression of PP2C or duplication of this chromosomal region contains both genes).

The above discussion provides a factual basis for the use of PPC2 in cancer detection and therapy. The methods used with and the utility of the present invention can be shown by the following non-limiting examples and accompanying figures.

EXAMPLES**GENERAL METHODS:****General methods in molecular biology:**

Standard molecular biology techniques known in the art and not specifically described were generally followed as in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1992), and in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1994).

Generation of antibodies against the PP2C

According to the PP2C amino acid sequence a synthetic oligopeptide will be synthesized. This oligopeptide will be injected to rabbits in order to generate polyclonal antibodies against PP2C. Western blot's analysis will be performed using these antibodies.

PP2C activity assay

PP2C gene product is purified from the mouse cells by general procedure, and its activity will be assayed by its ability to dephosphorylate [³²P] casein (McGowan and Cohen, 1988).

Antisense RNA

Artificial antisense RNA complementary to the PP2C gene is synthesized, and transfected to the mouse cells by the method of Inouye (1988).

Identification of unique changes in gene expression by differential display

In order to detect changes in the expression of cellular genes mediated by AAV integration, the differential display method is used (Liang and Pardee, 1992; McClelland et al., 1995). This method is

directed toward the identification of differentially expressed genes among approximately 15,000 individual mRNA species in a pair of mammalian cell population such as infected and uninfected cells, and recovering their cDNA and genomic clones. The strategy of the method consists of the following steps: (1) Reverse transcription in fractions using a set of anchored primers, (2) amplification of cDNA species from each fraction using a set of arbitrary primers and anchored primers by labeled PCR, (3) electrophoretic separation of the resulting fragments on sequencing gel, (4) reamplification of fragments that are different in the two situations, cloning and sequencing, and (5) confirmation of differential expression by an independent RNA analysis technique.

Chromatin structure in latently infected cells

Higher order chromatin structure may affect the transcription of cellular genes. Judging by their increased sensitivity to digestion with Dnase I or micrococcal nuclease, transcriptionally active chromatin regions are less tightly packed than chromatin containing transcriptionally inactive genes. Chromatin will be partially purified and digested by micrococcal nuclease (Rcch et al., 1990). Purified DNA fragments will be digested with a unique restriction enzyme to generate a series of fragments with one end defined by micrococcal nuclease and the other defined by the restriction enzyme. Fragments will be separated by agarose gel electrophoresis, transferred to nitrocellulose filters and probed with labeled DNA fragments. Naked DNA will be purified and processed similarly. Nucleosome position and nuclease sensitive regions will be inferred by comparison of fragments from naked DNA and chromatin.

The methylation state of genes can indicate chromatin changes. Gene specific DNA methylation is measured by the methylation assay (Kafri et al., 1992). In this method, total cellular DNA is digested with
5 methyl-sensitive enzymes, such as HpaII or HhaI, and specific fragments of DNA that contain these sites are amplified by flanking oligonucleotide primers. If a specific site is methylated, the amplification will proceed normally. On the other hand, the presence of
10 an unmethylated site will result in digestion of the fragment and the subsequent failure to visualize the amplification product. When properly calibrated, this assay is linear over a wide range of DNA concentrations and can be used to accurately measure the degree of DNA
15 methylation at specific sites.

Identification of unique changes in gene expression by differential display

Total RNA is isolated from cells as described by
20 Sambrook et al. The RNA is reverse transcribed with an oligo dT primer designed to bind to the 5' boundary of the poly A tail. The cDNA is amplified in a PCR reaction with the oligo dT primer and a second 10-mer arbitrary in sequence. 40 cycles of PCR are done in
25 the presence of [³⁵S]-dATP, in the following conditions: 94°C for 30 seconds, 42°C for 60 seconds and 72°C for 30 seconds. The amplified cDNAs were separated on a 6% sequencing gel, then exposed to X-ray film.

30 Bands of interest (bands that are differentially displayed) are cut out from the gel, and reamplified with the same primers as used to generate the original PCR product. To confirm differential regulation of individual candidate bands, Northern blot
35 hybridizations is performed. Fragments of interest will be cloned using a TA cloning Kit, and sequenced.

Genes detected by this method are hybridized to Northern blots from the appropriate cells.

EXAMPLE OF STUDIES WITH AAV

5 A. Infection of mouse cells with AAV:

A1. Generation of mouse cells with stably integrated AAV:

10 The DA3 cell line was derived from the in-vivo D1-DMBA-3 mammary tumor syngeneic to BALB/C mice. The DA3 cell line produces tumors in BALB/C mice with the same growth kinetics and expresses the same tumor associated Ag on its surface as the parental tumor. The cells express specific markers for tumor cells, and
15 cease to express specific Ag typical to normal breast cells (Sotomayor et al., 1991).

To assess the influence of AAV on mouse cells, DA cells were infected with the JDT277 AAV/neo hybrid virus (Tratschin, 1985). JDT277 contains the portion of the
20 AAV2 genome, which encodes the Rep proteins, the AAV terminal inverted repeats (TIRs) and the prokaryotic neomycin phosphotransferase gene (neo), conferring resistance to G418. The neo gene was inserted at nucleotide 1882, resulting in carboxy terminus
25 truncated Rep proteins. The truncation of the Rep proteins does not affect the ability of the AAV/neo virus to replicate in Adeovirus coinfecting human cells.

30 Single colonies were isolated and amplified by serial passages in the presence of G418. The resistant cells were designated DA35.

Generation of DA3 cells with stably integrated AAV:

35 DA3 cells were infected with the JDT277 AAV/neo hybrid virus according to Winocour et. al. (1992), with slight

modifications. Single colonies were isolated and amplified by serial passages in the presence of the antibiotic G418. The resistant cell lines were designated DA3J.

5

A2. Characterization of the AAV genome in the DA3J cells:

a. Southern analysis

Genomic DNA isolated from DA3J1 - DA3J7 clones was
10 digested with different restriction enzymes (BglII or EcoRI), electrophoresed and hybridized to radiolabelled AAV DNA. The hybridization pattern is different in each clone, probably due to rearrangement of the AAV genome. Indeed it is known that integration of AAV DNA
15 is frequently accompanied by alterations within the viral sequences (Walz and Schlehofer, 1992).

b. PCR analysis

To find whether the rep promoters and ORF's were present in the DA3J cell lines, PCR reactions were
20 carried on 7 clones (DA3J1 - DA3J7), using different oligonucleotide primers complementary to the AAV and neo sequences. The results demonstrated that parts of the viral sequences in each clone were somehow interrupted. In all the examined cell lines the AAV
25 rep ORF's were not intact, thus, impairing the expression of the AAV specific proteins.

In two clones, DA3J3 and DA3J4, two AAV molecules integrated into the host genome in a head-to-tail pattern. This finding is in agreement with earlier
30 studies showing that the AAV DNA recombined into the Chinese hamster host DNA, at least in some cases, as a head-to-tail concatamer of more than one viral genome, via the terminal sequences of the viral molecule (Cheung et al., 1980; Walz and Schlehofer, 1992).

35

A3. Expression of AAV genes in the infected DA3J cells:

Cell extracts from the infected DA3 were prepared according to Winocour et al. (1992). Samples from the
5 extracts were electrophoresed on a 12% PAGE, and immunoblotted with an anti-Rep antibody. The results showed that, the two major Rep proteins, Rep78 and Rep68, are not expressed in any of the infected cells, however one of the small Rep proteins, Rep40, is
10 expressed in two clones, DA3J11 and DA3J13. These results were expected from the PCR analysis that showed that in all the examined cell lines the rep ORF's were not intact.

15 B. Site specific integration

B1. Comparison of the integration site of AAV in the mouse cells with the AAV integration site in the Chinese hamster cells:

20 Genomic DNA from parental DA3 and DA3J clones (DA3J1 - DA3J7) was digested with BglII or EcoRI. Following electrophoresis the blots were hybridized once with the cellular sequence from the virus/cell junction, isolated from C9-3 (clone 6), and once with
25 radiolabelled AAV DNA. In three of the cell lines (DA3J3, DA3J4 and DA3J6) the cellular probe and the AAV probe hybridized to common bands. Using PP2C probe applicant found in BglII digested DNA that both AAV and PP2C hybridized to the same bands. Thus, both in
30 Chinese hamster and mouse AAV always integrated into the same site in the vicinity of PP2C. Note that in all cell lines including the parental DA3 cells. PP2C and the cellular clone 6 probes hybridized to the same band which is the preintegration site.

B2. Cloning the integration site of AAV in the DA3J cells:

Attempts to clone the flanking region of the integrated AAV from one of the DA3J clones, by inverse PCR were so far unsuccessful. Independent attempts to clone the flanking region of AAV from C9-3, by this method were also not successful. The difficulties arose probably due to the secondary structure at the ends of the AAV genome, which interfered with the polymerization by the Taq polymerase.

C. Effect of AAV on the cellular phenotype:

The following cytological properties were compared between DA3 infected and parental cells:

a. Plating efficiency

As shown in Table 1, the plating efficiency of the DA3J cells was reduced compared to the plating efficiency of the parental DA3 cells, by 11% (DA3J2) to 54% (DA3J3).

b. Sensitivity to UV irradiation

As shown in Table 2, the DA3J cells show increased sensitivity to UV irradiation compared to the parental DA3 cells. There is a decrease of 5% to 55% in the survival rate of the DA3J cells compared to the DA3 cells.

These results are in agreement with other studies, which demonstrated that AAV infected cells (HeLa, CO60) show reduced plating efficiency, and enhanced sensitivity to UV irradiation, compared to uninfected cells (Walz and Schlehofer, 1992; Winocour et al., 1992).

It is interesting to note that, DA3J3 shows the lowest plating efficiency, and the highest sensitivity to UV irradiation. This may be due to the fact that DA3J3 contains two integrated AAV molecules, while DA3J1 and DA3J2, contains only one.

c. FACS analysis

FACS analysis was performed on DA3, DA3J1, DA3J2, and DA3J3 as described by Vindelov et. al., (Vindelov et al., 1983). In this procedure no significant
5 changes were observed between the parental DA3 cells and the DA3J cells.

Throughout this application, various publications patents, are referenced by citation and patents by patent number. Full citations for the publications are
10 listed below. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an
15 illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of
20 the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

25

Table 1. Plating efficiency of the DA₃J clones compared with that of the parental DA₃ cell line

No. of cells plated	No. of outgrowing colonies (mean \pm SD), % of plating efficiency			
	DA ₃	DA ₃ J ₁	DA ₃ J ₂	DA ₃ J ₃
250	88 (6) 35%	53 (8) 21%	78 (11) 31%	43 (5) 17%
500	181 (36) 36%	103 (10) 20%	131 (20) 26%	82 (9) 17%

Semiconfluent cells derived from DA₃, DA₃J₁, DA₃J₂, and DA₃J₃ cell cultures were seeded at 250 and 500 cells onto 9-cm plastic petri dishes. Cultures were grown for 7 days. Cells were then fixed and stained with Gimsa. The mean number of growing colonies from two experiments was determined. Each experiment was performed in triplicates.

Table 2. UV sensitivity of the DA₃J clones compared with that of the parental DA₃ cell line

J/m ²	No. of outgrowing colonies (mean \pm SD), % of survival							
	DA ₃		DA ₃ J ₁		DA ₃ J ₂		DA ₃ J ₃	
0	91 (4)	100%	59 (20)	100%	79 (6)	100%	36 (7)	100%
2.5	85 (5)	95%	54 (9)	91%	85 (8)	100%	36 (4)	100%
5	62 (5)	68%	25 (30)	42%	39 (13)	49%	11 (11)	30%
10	22 (6)	24%	12 (2)	20%	19 (4)	24%	4 (2)	11%
20	0 (0)	0%	0 (0)	0%	2 (2)	2%	0 (0)	0%

Semiconfluently growing cells from DA₃, DA₃J₁, DA₃J₂, and DA₃J₃ cell cultures were seeded at 250 cells onto 9-cm plastic petri dishes. After 48 hours the cultures were irradiated with UV light, and then incubated for 7 days. The mean number of growing colonies was determined. The experiment was performed in triplicates.

REFERENCES

- Fodor et al, "Multiplexed biochemical assays with biological chips", Nature 364:555-556 (1993)
- Gilboa, E, Eglitis, MA, Kantoff, PW, Anderson, WF: Transfer and expression of cloned genes using retroviral vectors. BioTechniques 4(6):504-512, 1986.
- Kawasaki ES. Amplification of RNA. In: PCR protocols. A Guide to Methods and Applications, Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. Academic Press, 1990, pp21-27.
- Lichter, et al., "High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones" Science 247:64-69 (1990).
- Orita M, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766-2770
- Pease et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis", Proc. Natl. Acad. Sci. USA 91(11):5022-5026 (1994)
- Burke and Olson, "Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors" in Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270 (1991).
- Capecchi, "Altering the genome by homologous recombination" Science 244:1288-1292 (1989).
- Davies et al., "Targeted alterations in yeast artificial chromosomes for inter-species gene transfer", Nucleic Acids Research, Vol. 20, No. 11, pp. 2693-2698 (1992).
- Dickinson et al., "High frequency gene targeting using insertional vectors", Human Molecular Genetics, Vol. 2, No. 8, pp. 1299-1302 (1993).
- Huxley et al., "The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion", Genomics, 9:742-750 (1991).

Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial chromosome", Nature, Vol. 362, pp. 255-261 (1993).

Lamb et al., "Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice", Nature Genetics, Vol. 5, pp. 22-29 (1993).

Rothstein, "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast" in Methods in Enzymology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 19, pp. 281-301 (1991).

Roth ET AL., "Yeast alpha 2 repressor positions nucleosomes in TRP1/ARS1 chromatin" Mol. Cell. Biol., 10:2247-2260 (1990).

Schedl et al., "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", Nature, Vol. 362, pp. 258-261 (1993).

Strauss et al., "Germ line transmission of a yeast artificial chromosome spanning the murine α_1 (I) collagen locus", Science, Vol. 259, pp. 1904-1907 (1993).

Aladjem, M. and Lavi, S. 1992. The mechanism of carcinogen-induced DNA amplification: In-vivo and in-vitro studies. Mutation Res. 276: 339-344.

Atchison, R.W., Casto, B.C. and Hammond, W.M. 1965. Adenovirus-associated defective virus particles. Science 149: 754-756.

Burstyn T. 1993. Suppression of SV40 DNA amplification by Adeno Associated virus. M.Sc. Thesis. Tel Aviv University.

Casto, B.C. and Goodheart, C.R. 1972. Inhibition of adenovirus transformation in vitro by AAV-1. Proc. Soc. Exp. Biol. Med. 140: 72-78.

Cohen, P. 1989. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 58: 453-508.

Cohen, P. 1991. classification of protein-serine/threonine phosphatases: identification and quantitation in cell extracts. *Methods. Enzymol.* 201: 389-399.

Cukor, G., Blacklow, N.R., Hoggan, D. and Berns, K.I. 1984. Biology of adeno-associated virus. In: Berns, K.I. (Ed.) *The Parvoviruses*. Plenum Press, New York, pp. 33-66.

de la Maza L. M., and Carter B. J., 1981. Inhibition of Adenovirus oncogenicity by Adeno-associated virus DNA. *J. Natl. Cancer Inst.* 67: 1323-1326.

Fukunaga, K., Kobayashi, T., Tamura, S. and Miyamoto, E. 1993. Dephosphorylation of autophosphorylated Ca^{2+} /calmodulin-dependent protein kinase II by protein phosphatase 2C. *J. Biol. Chem.* 268: 133-137.

Gavrieli, Y., Sherman, Y and Ben Sasson, S.A. 1992, Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J. Cell. Biol.* 119:439-501.

Georg-Fries, B., Biederlack, S., Wolf, J. and zur Hausen, H. 1984. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. *Virology* 134: 64-71.

Hermonat P.L., 1989. The Adeno-associated virus rep78 gene inhibits cellular transformation induced by Bovine Papillomavirus. *Virology.* 172: 253-261.

Hermonat P.L., 1994. Down regulation of the human c-fos and c-myc proto-oncogene promoters by Adeno-associated virus rep78. *Cancer Lett.* 81: 129-136.

Katz, E. and Carter, B.J. 1986. Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line.

Kirschstein, R.L., Smith, K.O. and Peters, E.A. 1968. Inhibition of adenovirus 12 oncogenicity by adeno-associated virus. *Proc. Soc. Exp. Biol. Med.* 128: 670-673.

Lavi, S. 1981. Carcinogen mediated amplification of viral DNA sequences in SV40 transformed Chinese hamster embryo cells. *Proc. Natl. Acad. Sci. USA* 78: 6144-6148.

Mayor, H.D., Houlditch, G.S. and Mumford, D.M. 1973. Influence of adeno-associated satellite virus on adenovirus-induced tumors in hamsters. *Nature New Biol.* 261: 44-46.

Mayor, H.D., Drake, S., Stanmann, J. and Mumford, D.M. 1976. Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. *Am. J. Obstet. Gynecol.* 126: 100-104.

Martin- Gallardo A., McMombie W. R., Gocayne J. D., FitzGerald M. G., Wallace S., Lee B. M. Lamerdin J., Trapp S., Kelley J. M. and Lia L., 1992. Automated DNA sequencing and analysis of 106 kilobases from human chromosome 19q13.3. *Nature Genetics.* 1: 34-39.

Ohishi, S. et al., *Biochem. Intl.* 28:345-351, 1992

Ostrove, J.M., Duckworth, D.H. and Berns, K.I. 1981. Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus. *Virology* 113: 521-533.

Robinson, M.K., van Zyl, W.H., Phizicky, E.M. and Broach, J.R. 1994. TPD1 of *Saccharomyces cerevisiae* encodes a protein phosphatase 2C-like activity implicated in tRNA splicing and cell separation. *Mol. Cell. Biol.* 14: 3634-3645.

Rommelaere J. and Tattersall P., 1990. Tijssen P. (ed.), *Handbook of Parvoviruses*. CRC, Boca Raton, pp. 41- 85.

Sato, R.J. and Mayor, H.D. 1979. Adenovirus-associated virus polypeptides synthesized in cells coinfecting with either adenovirus or herpesvirus. *Virology* 93: 237-245.

Schlehofer J. R. Ehrbar M. and zur Hausen H., 1986. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in human cell line and support replication of herpesvirus dependent parvovirus. *Virology.* 152: 110-117.

Schlehofer, J.R. and zur Hausen, H. 1982. Induction of mutations within the host cell genome by partially inactivated herpes simplex virus type 1. *Virology* 122: 471-475.

Shiozaki, K. and Russel, P. 1995. Counteractive roles of protein phosphatase 2C (PP2C) and a MAP kinase homolog in the osmoregulation of fission yeast. *EMBO J.* 14: 492-502.

Shiozaki, K., Akhavan-Niaki, H., McGowan, C.H. and Russel, P. 1994. Protein phosphatase 2C, encoded by *ptc1+*, is important in the heat shock response of *Schizosaccharomyces pombe*. *Mol. Cell. Biol.* 14: 3742-3751.

Siegl, C., Bates, R.C., Berns, K.I., Carter, B.J., Kelly, D.C., Kurstak, E. and Tattersel, P. 1985. Characteristics and taxonomy of Parvoviridae. *Intervirology* 23: 61-73.

Sotomayor E. M., Fu Y., Lopez-Cepero M., Herbert L., Jimenes J. J., Albaracin C. and Lopez D. M., 1991. Role of the tumor derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. *J. Immunol.* 147: 2816-2823.

Sprecher-Goldberger, S., Thiry, L., Lefebvre, N., Dekegel, D. and de Halleux, P. 1971. Complement-fixation antibodies to adeno-associated viruses, adenoviruses, cytomegaloviruses and herpes simplex viruses in patients with tumors and in control individuals. *Am. J. Epidemiol.* 24: 351-358.

Taylor, I.W. (1980). *J. Histochem. Cytochem.* 28: 1021.

Wijnsman, J.H., Jonker, R.R., Keijzer, R., van de Velde, C.J.H., Cornelisse, C.J. and van Dierendonck, J.H. 1993. A new method to detect apoptosis in paraffin sections: in-situ end-labeling of fragmented DNA. *J. Histochem. Cytochem.* 41: 7-12.

Winocour E., Koch T., Danovich B., Mendelson E., Shaulian E., Karby S. and Lavi S., 1992. Modulation of the cellular phenotype by integrated Adeno-associated virus. *Virology*. 190: 316-329.

Yakobson B., Hrynko T. A., Peak M. J. and Winocour E., 1989. Replication of Adeno-associated virus in cells irradiated with UV light at 254 nm. J. Virol. 63: 1023-1030.

Young, J.F. and Mayor, H.D. 1979a. Adeno-associated virus - an extreme state of viral defectiveness. Prog. Med. Virol. 25: 113-132.

Young, J.F. and Mayor, H.D. 1979b. Studies on the defectiveness of adeno-associated virus (AAV). 1. Effects of phosphonoacetic acid and 2-deoxy-D-glucose on the replication of AAV. Virology 94: 323-341.

Berns K. I., 1990. Parvovirus replication. Microbiol. Rev. 54: 316-332.

Cheung A. K., Hoggan M. D., Hauswirth W. W. and Berns K. I. 1980. Integration of the Adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J. Virol. 33: 739-748.

Inouye M. 1988. Antisense RNA: its functions and applications in gene regulation - a review. Gene. 72: 25-34.

Kafri. T., Ariel M., Brandeis M., Shemer R., Urven L., McCarrey J., Howard C. and Razin A., 1992. Developmental pattern of gene-specific DNA methylation in mouse embryo and germ line. Genes Dev. 6: 705-714.

Leonard C. J. and Berns K. I., 1994. Adeno-associated viruses type 2: a latent life cycle. Proc. Natl. Acad. Sci. USA. 48: 29-52.

Liang P. and Pardee A. B., 1992. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257: 967-971.

McClelland M., Mathieu-Daude and Wlsh J., 1995. RNA fingerprinting and differential display using arbitrarily primed PCR. TIG. 11: 242-246.

McGowan C. H. and Cohen P., 1988. Protein phosphatase-2C from rabbit skeletal muscle and liver: an Mg²⁺ dependent enzyme. Methods Enz. 159: 416-426.

Tratschin J. D., 1985. Adeno associated virus vector for high frequency of integration, expression, and rescue of genes in mammalian cells. *Mol. Cell. Biol.* 5: 3251-3260.

Vindelov L. A., Christensen I. J. and Nissen N. I., 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. *Cytometry* 3: 323-327.

Walz C. and Schlehofer J. R. 1992. Modification of some biological properties of Hela cells containing Adeno associated virus DNA integrated into chromosome 17. *J. Virol.* 66: 2990-3002.

CLAIMS

What is claimed is:

- 5 1. A method of detecting cancer in a patient by detecting PP2C gene activity in a specimen containing cells isolated from the patient.
2. The method of claim 1 wherein the detecting of 10PP2C activity is by assaying the specimen for mRNA complementary to PP2C DNA including polymorphisms thereof with an assay selected from the group consisting of *in situ* hybridization, Northern blotting and reverse transcriptase - polymerase chain reaction.
- 15 3. The method of claim 1 wherein the detecting of PP2C activity is by assaying the specimen for a PP2C gene product including polymorphisms thereof with an assay selected from the group consisting of 20immunohistochemical and immunocytochemical staining, ELISA, RIA, immunoblots, immunoprecipitation, Western blotting, functional assays and protein truncation test.
- 25 4. A kit for detecting PP2C activity, said kit comprising:
a molecular probe complementary to genetic sequences of a mRNA for PP2C including polymorphisms thereof and
30 detection means for detecting hybridization of said molecular probe and the mRNA thereby indicating the activity of the defective gene.
- 35 5. A kit for detecting a gene product associated with PP2C gene activity, said kit comprising:

an antibody which recognizes the PP2C gene product including polymorphisms thereof, and detection means for detecting the binding of the antibody thereby indicating the presence of the 5gene product.

6. The kit as set forth in claim 5 further characterized by the detecting means utilizing agents which mimic natural proteins with which bind to the 10PP2C gene product.

7. A non-human transgenic mammal or cell line containing an expressible nucleic acid sequence for PP2C including polymorphisms thereof.

15

8. A non-human eucaryotic organism in which the equivalent nucleic acid sequence for PP2C is knocked-out.

20 9. A vector comprising an expression control sequence operatively linked to the nucleic acid sequence of PP2C.

10. A vector comprising an antisense sequence of 25PP2C.

11. An antibody which specifically binds to an epitope of a gene product of PP2C including polymorphisms thereof.

30

12. An antibody of claim 10 selected from the group consisting of monoclonal and polyclonal antibody.

13. An antibody of claim 11 conjugated to a 35detectable moiety.

14. A method of treating cancer including the steps of

- a. determining the type of cancer and cells expressing the cancer,
- 5 b. preparing a vector which will specifically target the cancer cells including regulatory elements to control the expressibility of PP2C, and
- c. administering the vector to the patient.

10 15. The method as set forth in claim 14 wherein the vector is a modified AAV.

16. The method as set forth in claim 14 wherein the vector contains the CHINT sequences.

15

17. A method of treating cancer including the steps of

- a. determining the type of cancer and cells expressing the cancer,
- 20 b. preparing an antisense vector which will specifically target the cancer cells to control the expressibility of PP2C, and
- c. administering the vector to the patient.

25

PR-314 (TAU)

5 MANIPULATION AND DETECTION OF PROTEIN
 PHOSPHATASE 2C - PP2C - EXPRESSION IN TUMOR
 CELLS FOR CANCER THERAPY, PREVENTION AND
 DETECTION

10 ABSTRACT OF THE DISCLOSURE

10 A method of detecting cancer in a patient by
 detecting activity of the gene coding for human type
 protein phosphatase 2C (PP2C) and genetic polymorphisms
15 thereof in a specimen containing cells isolated from
 the patient is disclosed. The invention further
 provides a method of treating cancer including the
 steps of first determining the type of cancer and cells
 expressing the cancer and then preparing a vector which
20 will specifically target the cancer cells and can
 include regulatory elements to control the
 expressibility of PP2C. The vector is then
 administered to the patient. Alternatively an
 antisense vector can be prepared.

PATENT

Attorney's Docket Number: PR-314 (TAU)

Applicant or Patentee: Sara Lavi
Serial or Patent No: _____
Filed or Issued: Herewith
For: MANIPULATION AND DETECTION OF PROTEIN
PHOSPHATASE 2C - PP2C - EXPRESSION IN
TUMOR CELLS FOR CANCER THERAPY.
PREVENTION AND DETECTION

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d))--SMALL BUSINESS CONCERN

I hereby declare that I am:

- ___ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act
on behalf of the concern identified below:

Name of Concern: Ramot-University Authority for Applied Research
and Industrial Development, Ltd.Address of Concern: 32 H. Javanon Street, P.O. Box 39296
Tel Aviv 61392, Israel

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement: (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when, either directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled:

MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE
2C - PP2C - EXPRESSION IN TUMOR CELLS FOR CANCER THERAPY,
PREVENTION AND DETECTION

By Inventor(s): Sara Lavi
Described in:

- ☒ the specification filed herewith.
___ application serial no. _____, filed _____
___ patent no. _____, issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

* NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME: _____

ADDRESS: _____

____ Individual ____ Small Business ____ Nonprofit Organization

NAME: _____

ADDRESS: _____

____ Individual ____ Small Business ____ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: Manuel Kvatinsky

Title in Organization: Assistant R&D Manager, Patents & Technology Transfer

SIGNATURE:  Date: 9-1-95

Name of Person Signing: Zvi Shushan



Title in Organization: General Manager


SIGNATURE:  Date: 9-1-95

Address of Persons Signing: 22 Haim Levadon Street
Tel Aviv 61192, Israel


(Small Entity-Small Business (Form 7-4)--Page 2 of 2)

FORM 7-4 _____






60/001114



60/003114




File: Shu..008
Total Events: 7000

Acquisition Date: 10-May-95
X Parameter: FL2-A (Linear)

Marker	Events	% Total	Mean	CV
All	7000	100.00	384.11	48.19
G0/G1	3355	47.93	394.88	14.49
S	943	13.47	569.28	7.41
G2+M	668	9.54	727.76	8.06
Ap.	1485	21.21	132.36	36.21

Key	Name	Parameter	Gate	
—	Shu..005	FL2-A	No Gate	Co60
—	Shu..008	FL2-A	No Gate	913





File: Shu..010
Total Events: 7000



Acquisition Date: 10-May-95
X Parameter: FL2-A (Linear)



Marker	Events	% Total	Mean	CV
All	7000	100.00	382.48	51.50
G0/G1	3019	43.13	393.54	14.79
S	938	13.40	574.35	7.10
G2+M	798	11.40	737.43	8.24
Ap.	1684	24.06	123.69	36.68



Key	Name	Parameter	Gate	
—	Shu 005	FL2-A	No Gate	Co60
—	Shu 010	FL2-A	No Gate	916

FIGURE 2












FIGURE 11





FIGURE 5

60/003114



60/003114

AAV Integration in 9-3




FIGURE 7

60/003114

ID HSMMDBC standard; DNA; PRI; 68505 BP.
 AC M89651; M77823; M77824; M77825;
 DT 09-MAY-1992 (Rel. 31, Created)
 DT 09-MAY-1992 (Rel. 31, Last updated, Version 1)
 DE Human DNA from cosmid DNA MMD (f10080) and MMD (f13544) from
 DE chromosome 19q13.3 (obtained by automated sequence analysis).

SCORES Init1: 61 Initn: 138 Opt: 82
 58.3% identity in 103 bp overlap

	20	30	40	50	60	70
int.1i	TAGTCCCGGTCAAGGAAC	TGAACGTGCGATTCCGGGACAGGCTACCCACTCCGATCCAG				
hsmdb	CCTCACCTCCGCCCTGTTTCGTCCAGGTCCTCCGGGTCAGGCTACCCCGTCGCCGCCA-					
	57710	57720	57730	57740	57750	57760
	80	90	100	110	120	130
int.1i	GAGAAGTTGTTCATGGTGAGGGCCACCCCTAGGTCTCTGCCCCCTGCTGTCTCCCATCTTA					
hsmdb	GAG-CGCGGGGGAGGGGAGAGCTTCCTTTGTCTCCTATGCTCTCT---CCCCCATCCCC					
	57770	57780	57790	57800	57810	57820
	140	150	160	170	180	190
int.1i	CCCATCCAGTAGGATCTAGAGGCTGTGCGCCCCCTTGTGGAATGCACAGATCACAAGCG					
hsmdb	GCTCTCCTGCGGGCAAGCGCGGAGGGGACACCGGGAGTATCCACCTGAACCTCTGGGG					
	57830	57840	57850	57860	57870	57880



(GCG - fasta)

FIGURE 8 A

60/003114

LOCUS HUMMMDB. 68505 bp ds-DNA PRI 09-APR-1992
gaps: 16 Quality: 92.3 Ratio: 0.246 Score: 38 Width: 34 Limits: -

```

16 GAGGGGGGGGTTGGGGGAC....TCTAGACAGGTGAGGCGG3AAAGCAT 61
57642 GAGGGGACACCGGGGAGTACCGGACCTGAACCTCTGGGGCCC....ACAC 57887
42 GAGTCCTCGGCTCTTCTC...CTCCTT.....CTCGGGGA 34
57882 CAGGGCCCCAG.TCTTCCTCTACTCACTGCAGTGGGCGAAGACCGGCAGCA 57936
35 CCGGCTCTCT. GCGTCCCTC.....TCCAACGCGCGGATGA 129
57937 CCTGCCCCCATGSCCCCCCTCGGGCTGCATCGGGACCCCTCGCCACTCCG 57985
130 TCTGAGCCG.....CGAGGGCGCCGA...CAGCCGGGGG 161
57987 GCTGTGCGCGCTTGGGCGCGGGGTGCGGGCGGCTCATCTCTCGCGCGCC 58035
162 CCG...GACGCAGCGCGGCTCTCGGCTCTCGCGCC...CTTCCCGAGCC 206
58037 ACGACGCGCTGCGCATTTCTCGCGGCTCTCTCTCGCGGGCTGATCCAG... 58084
207 TGACCTGGCGCGCGGCTGCAGCGGTGACCCCTCGCGCGGCTCGCGGCTC 256
58085 .....CGCGCGCC.....CGCGCGCGCGCGCGCG 58110
257 GCGCGCGCGGTTGACCGCTCTCGCGGGCTGCGCGCGCGCGCC..... 295
58111 GCGCGCGCTGCTGCTCGGCTCGCGGGGCGGGCGGGCGGCGAGGTGGGGA 58160
296 .....GCGTGGCGGACCGGACCTGCC.....CGCTGCGGGTGC 332
58161 GGCACCTGCAGCGCGCGCGGGGCGGGGCGGAGACGGGCGGGCGGT 58210
333 TCGCG.....ACCTAGAGGATCAAG 352
58211 ACCAGAGGGAGGGTGAGGGGCGGGGAAACGCGGAGGATCAGG 58252

```

FIGURE 8 B




FIGURE 9 A




FIGURE 9 B

60/003114





FIGURE 10



51/1001e

